低b值扩散加权成像序列能否替代乳腺MRI标准T2加权流体敏感序列?一项单中心前瞻性研究
这项单中心前瞻性研究纳入72例女性(平均年龄48.3±12.5岁)的121个病灶,由5名放射科医师独立评分,比较低b值(b0)DWI与标准T2加权/流体敏感STIR序列的病灶显示清晰度、信号特征和伪影。结果显示DWI在病灶清晰度不劣于STIR的评估占88.8%(p<0.001),信号特征跟随STIR的评估占96.9%(p<0.001),无或轻度伪影的评估占98.3%(p<0.001)。作者结论认为低b值DWI提供与STIR相似的诊断能力。
要点
- 低b值(b0)DWI在病灶清晰度上不劣于STIR的评估占88.8%(p<0.001)。
- DWI信号特征跟随STIR的评估占96.9%(p<0.001),无或轻度伪影占98.3%(p<0.001)。
- DWI与STIR病灶清晰度相似的一致性为89.9%(κ=0.790,95%CI 0.76-0.82)。
核心结论
- 低b值DWI提供与T2加权/流体敏感STIR相似的诊断能力,病灶清晰度和信号特征相当且无明显伪影。
研究设计与样本
- 前瞻性单中心研究,72例女性(平均年龄48.3±12.5岁)的121个病灶,5名放射科医师独立评分,使用3-T或1.5-T乳腺MRI,包含标准T2加权/流体敏感STIR序列和研究性DWI序列(rs-EPI联合SMS成像)。
关键影像表现/征象
- DWI病灶清晰度不劣于STIR的评估为537/605(88.8%,p<0.001)。
- DWI信号特征跟随STIR的评估为586/605(96.9%,p<0.001)。
- DWI无或轻度伪影的评估为595/605(98.3%,p<0.001)。
诊断标准与关键数值
- 病灶清晰度相似的一致性为89.9%(κ=0.790,95%CI 0.76-0.82)。
- 病灶信号特征相似的一致性为95.7%(κ=0.733,95%CI 0.69-0.77)。
- DWI轻度/无伪影与中度/明显伪影区分的一致性为97.2%(κ=0.515,95%CI 0.29-0.75)。
临床应用与阅片要点
- 作者结论认为低b值DWI可提供与STIR相似的诊断能力,病灶清晰度和信号特征相当且无明显伪影。
- 作者指出纳入低b值DWI可通过减少假阳性和缩短总扫描时间改善乳腺MRI的成本效益和患者体验。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine whether a low b-value (b0) diffusion-weighted imaging (DWI) sequence of a similar acquisition time can fulfill the role of a T2-weighted/fluid-sensitive short tau inversion recovery (STIR) sequence.
MATERIALS AND METHODS: In this prospective, single-institutional study, participants underwent 3-T or 1.5-T breast MRI, which included a standard T2-weighted/fluid-sensitive short TI inversion recovery (STIR) sequence and an investigational DWI sequence (comprising readout segmented echo planar imaging (rs-EPI) and simultaneous multi-slice (SMS) imaging). Five radiologists independently scored 121 lesions on imaging by answering three questions assessing lesion conspicuity, lesion signal characteristics, and artifact grading. Statistical analysis included one-sample tests of proportions and Nelson's model kappa.
RESULTS: From 605 assessments in 72 patients (mean age, 48.3 ± 12.5 years [standard deviation]; 72 women), 537 (88.8%, p < 0.001) received assessments that lesion conspicuity on DWI was not inferior to STIR, 586 (96.9%, p < 0.001) received assessments that DWI followed the lesion signal characteristics on STIR, and 595 (98.3%, p < 0.001) received assessments that there were no or mild artifacts on DWI. Inter-reader agreement was substantial for similar lesion conspicuity (89.9%, к = 0.790, 95% CI: 0.76-0.82) and similar lesion signal characteristics (95.7%, к = 0.733, CI 0.69-0.77) on DWI and STIR, and moderate for whether there was mild/no artifact vs. moderate/substantial artifact on DWI (97.2%, к = 0.515, CI: 0.29-0.75).
CONCLUSION: Low b-value DWI provides similar diagnostic capabilities as T2-weighted/fluid-sensitive STIR, with comparable lesion conspicuity and lesion signal characteristics and without significant artifacts.
KEY POINTS: Question Can diffusion-weighted imaging (DWI) be incorporated into clinical 1.5-T and 3-T breast MRI protocols without adding acquisition time? Findings The signal characteristics and conspicuity of breast lesions on low b-value (b0) DWI were not inferior compared with that on standard T2-weighted/fluid-sensitive imaging. Clinical relevance The incorporation of low b-value DWI can translate to improved cost-effectiveness and patient experience of breast MRI by reducing false-positives and reducing overall scan time.
引用
- Gatewood J, Peterson J, Aripoli A, et al. Can a low b-value diffusion-weighted imaging sequence replace the standard T2-weighted fluid-sensitive sequence in breast MRI? A single-center prospective study. Eur Radiol. 2025. PMID: 40335657. doi:10.1007/s00330-025-11624-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。